Search results - 14 results

VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples

aims to compare the clinical sensitivity and specificity of particular hrHPV assay(s) on vaginal self-samples and first-void-urine, collected in agreement with standardized protocols, with hrHPV testing ...

Clinical Evaluation of INNO-LiPA HPV Genotyping II Assay Using the VALGENT Framework.

HC2 (relative sensitivity of 1.01; 95% CI, 0.97⁻1.04; = 0.0002) and a specificity for ≤ CIN1 of 85.3% (95% CI, 83.2⁻87.3%) which was inferior to HC2 (relative specificity of 0.95; 95% CI, 0.93⁻0.97; ...

Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?

relative sensitivity and specificity compared to Hybrid Capture-2 or GP5 +/6+ PCR –enzyme immunoassay. These latter two hrHPV DNA assays were validated in large randomized trials and cohorts with a follow-up ...

Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.

Oligonucleotide Probes Papillomaviridae Papillomavirus Infections Reference Standards Sensitivity and Specificity Young adult Abstract: The LMNX genotyping kit HPV GP (LMNX) is based on the clinically validated GP5 ...

QR code

QR code for this page URL